1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 9 DRUG DISCOVERY: FINDING A LEAD Part 1: Sections 9.1-9.3.

Slides:



Advertisements
Similar presentations
Introduction to Anatomy and Physiology
Advertisements

The Drug Discovery Process
Postgraduate Course in Pharmaceutical Medicine A warm welcome to all participants.
Introduction to Pharmacology
DRUG-RECEPTOR INTERACTIONS
CHAPTER 10 Basic Biopharmaceutics
Bioinformatics Ayesha M. Khan Spring Phylogenetic software PHYLIP l 2.
Drug Discovery and Development How are drugs discovered and developed?
BASIC BIOCHEMISTRY MLAB Introduction. INTRODUCTION TO BASIC BIOCHEMISTRY Biochemistry can be defined as the science concerned with the chemical.
Chapter 12. Target disease Priority for the Pharmaceutical Industry: Can the profits from marketing a new drug outweigh the cost of developing and testing.
Drug Discovery & Development
Optimizing Target Interactions
Drugs Drugs & Medicine Emma Mackenzie December 19 th 2012 IB 12.
Biotechnology in Medicine Chapter 12.
Unit 3 Biology: signatures of life conceptual framework
© 2012 The McGraw-Hill Companies, Inc. All rights reserved. 1 Pharmacology: An Introduction CHAPTER.
Principles of Pharmacology: Pharmacodynamics
Anti-mRNA Strategies What is the antisense oligonucleotides? - Synthetic genetic material. - Interacts with natural genetic material (DNA or RNA) prevent.
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation. Fundamentals of Pharmacology for Veterinary Technicians Chapter 4 Pharmacokinetics.
PHC 222 Medicinal Chemistry-1- Part(I) Dr. Huda Al Salem Lecture (1)
Pharmacology UG-Course Touqeer Ahmed PhD 19 th February, 2015 Atta-ur-Rahman School of Applied Biosciences National University of Sciences and Technology.
1 Antimicrobial Drugs. 2 Antimicrobal Chemotherapy Terms.
Chapter 4 Pharmacokinetics Copyright © 2011 Delmar, Cengage Learning.
1 Biological Discovery High Volume Screening Combinatorial Diversity Structure, Design, Informatics Lead Series Biodisposition Toxicity Efficacy Pharmacokinetics.
Mark Fang Stanford iGEM 08-09
1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 10 DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS Part 2: Section 10.2.
1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 10 DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS Part 1: Section 10.1 (SAR)
BASIC PHARMACOLOGY 2 SAMUEL AGUAZIM(MD).
Big Ideas Technological applications that affect biological processes and cellular functions are used in the food, pharmaceutical, and medical industries.
© Paradigm Publishing, Inc.1 Chapter 2 Basic Concepts of Pharmacology.
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
Introduction to Pharmacology Yacoub Irshaid MD, PhD, ABCP Department of Pharmacology.
1 © 2. DRUG TARGETS Between species Antibacterial and antiviral agentsAntibacterial and antiviral agents Identify targets which are unique to the invading.
DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS
Basic Concepts of Pharmacology © Paradigm Publishing, Inc.
Shows tendency for mergers. These big companies may be shrinking – much research is now outsourced to low cost countries like Latvia, India, China and.
Drug Discovery & Development
Molecular Modeling in Drug Discovery: an Overview
DRUG RECEPTORS AND PHARMACODYNAMICS
Pharmacodynamics. * The study of the biochemical and physiologic effects of drugs and the molecular mechanisms by which those effects are produced * The.
Pharmacology Science that studies interactions of drugs with organism on different levels (subcellular, cellular, organ, systemic) Studies: - relationship.
DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS
5 Pharmacodynamics.
Drug Discovery &Development
Medicinal Chemistry III
Can Drug Discovery Research be Done At An Undergraduate Institution?
NUCLEIC ACIDS AS DRUG TARGETS
MBBS-BDS LECTURE NOTES
APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY
Biotechnology Objectives: At the end of this lecture we will be able to identify and describe the uses of biotechnology in society.
Understanding the Basics of Pharmacology
Discovery and Development of Medicines
An Introduction to Medicinal Chemistry 3/e
Biopharmaceutics Dr Mohammad Issa Saleh.
5 Pharmacodynamics.
INTRODUCTION to Pharmacology
Pharmacologic Principles – Chapter 2
Insight into the Pharmaceutical Industry
An Introduction to Medicinal Chemistry 3/e PROTEINS AS DRUG TARGETS:
Chemical Compounds Chapter 3 Section 1 Notes.
Pharmacology UG-Course
Drug Design and Drug Discovery
An Introduction to Medicinal Chemistry 3/e PROTEINS AS DRUG TARGETS:
Pharmacodynamic Dr. Hashem Mansour.
By Amany Helmy Hasanin Assistant Professor of Clinical Pharmacology
By Amany Helmy Hasanin Assistant Professor of Clinical Pharmacology
INDUSTRIAL PHARMACEUTICAL CHEMISTRY (CHEM606/612)
Medicinal chemistry Option D Part 1.
Patrick: An Introduction to Medicinal Chemistry 6e
Pharmacodynamics BSCI 493 March 2008.
Presentation transcript:

1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 9 DRUG DISCOVERY: FINDING A LEAD Part 1: Sections

1 © Contents 1.Target disease 2.Drug Targets (2 slides) 3.Testing Drugs 3.1.In vivo Tests 3.2.In vitro Tests Enzyme Inhibition Tests Testing with Receptors [10 slides]

1 © DRUG DESIGN AND DEVELOPMENT Stages 1) Identify target disease 1) Identify target disease 2) Identify drug target 2) Identify drug target 3) Establish testing procedures 3) Establish testing procedures 4) Find a lead compound 4) Find a lead compound 5) Structure Activity Relationships (SAR) 5) Structure Activity Relationships (SAR) 6) Identify a pharmacophore 6) Identify a pharmacophore 7) Drug design- optimising target interactions 7) Drug design- optimising target interactions 8) Drug design - optimising pharmacokinetic properties 8) Drug design - optimising pharmacokinetic properties 9) Toxicological and safety tests 9) Toxicological and safety tests 10) Chemical development and production 11) Patenting and regulatory affairs 12) Clinical trials

1 © 1. TARGET DISEASE Priority for the Pharmaceutical Industry Can the profits from marketing a new drug outweigh the cost of developing and testing that drug?Can the profits from marketing a new drug outweigh the cost of developing and testing that drug? Questions to be addressed Is the disease widespread?Is the disease widespread? (e.g. cardiovascular disease, ulcers, malaria) Does the disease affect the first world?Does the disease affect the first world? (e.g. cardiovascular disease, ulcers) Are there drugs already on the market?Are there drugs already on the market? If so, what are there advantages and disadvantages?If so, what are there advantages and disadvantages? (e.g. side effects) Can one identify a market advantage for a new therapy?Can one identify a market advantage for a new therapy?

1 © 2. DRUG TARGETS A) LIPIDS Cell Membrane Lipids B) PROTEINS Receptors Enzymes Carrier Proteins Structural Proteins (tubulin) C) NUCLEIC ACIDS DNA RNA D) CARBOHYDRATES Cell surface carbohydrates Antigens and recognition molecules

1 © 2. DRUG TARGETS Between species Antibacterial and antiviral agentsAntibacterial and antiviral agents Identify targets which are unique to the invading pathogenIdentify targets which are unique to the invading pathogen Identify targets which are shared but which are significantly different in structureIdentify targets which are shared but which are significantly different in structure Within the body Selectivity between different enzymes, receptors etc.Selectivity between different enzymes, receptors etc. Selectivity between receptor types and subtypesSelectivity between receptor types and subtypes Selectivity between isozymesSelectivity between isozymes Organ selectivityOrgan selectivity TARGET SELECTIVITY

1 © 3. TESTING DRUGS Tests are required in order to find lead compounds and for drug optimisationTests are required in order to find lead compounds and for drug optimisation Tests can be in vivo or in vitroTests can be in vivo or in vitro A combination of tests is often used in research programmesA combination of tests is often used in research programmes

1 © 3.1 in vivo Tests Carried out on live animals or humansCarried out on live animals or humans Measure an observed physiological effectMeasure an observed physiological effect Measure a drug’s ability to interact with its target and its ability to reach that targetMeasure a drug’s ability to interact with its target and its ability to reach that target Can identify possible side effectsCan identify possible side effects Rationalisation may be difficult due to the number of factors involvedRationalisation may be difficult due to the number of factors involved Transgenic animals - genetically modified animalsTransgenic animals - genetically modified animals Drug potency - concentration of drug required to produce 50% of the maximum possible effectDrug potency - concentration of drug required to produce 50% of the maximum possible effect Therapeutic ratio/index - compares the dose level of a drug required to produce a desired effect in 50% of the test sample (ED 50 ) versus the dose level that is lethal to 50% of the sample (LD 50 )Therapeutic ratio/index - compares the dose level of a drug required to produce a desired effect in 50% of the test sample (ED 50 ) versus the dose level that is lethal to 50% of the sample (LD 50 )

1 © Tests not carried out on animals/humansTests not carried out on animals/humans Target molecules (e.g. isolated enzymes or receptors) Cells (e.g. cloned cells) Tissues (e.g. muscle tissue) Organs Micro-organisms (for antibacterial agents) More suitable for routine testingMore suitable for routine testing Used in high throughput screeningUsed in high throughput screening Measure the interaction of a drug with the target but not the ability of the drug to reach the targetMeasure the interaction of a drug with the target but not the ability of the drug to reach the target Results are easier to rationalise - less factors involvedResults are easier to rationalise - less factors involved Does not demonstrate a physiological or clinical effectDoes not demonstrate a physiological or clinical effect Does not identify possible side effectsDoes not identify possible side effects Does not identify effective prodrugsDoes not identify effective prodrugs 3.2 in vitro Tests

1 © Identify competitive or non competitive inhibitionIdentify competitive or non competitive inhibition Strength of inhibition measured as IC 50Strength of inhibition measured as IC 50 IC 50 = concentration of inhibitor required to reduce enzyme activity by 50%IC 50 = concentration of inhibitor required to reduce enzyme activity by 50% Enzyme Inhibition Tests

1 © Not easy to isolate membrane bound receptorsNot easy to isolate membrane bound receptors Carried out on whole cells, tissue cultures, or isolated organsCarried out on whole cells, tissue cultures, or isolated organs Affinity - strength with which compounds bind to a receptorAffinity - strength with which compounds bind to a receptor Efficacy - measure of maximum biochemical effect resulting from binding of a compound to a receptor.Efficacy - measure of maximum biochemical effect resulting from binding of a compound to a receptor. Potency - concentration of an agonist required to produce 50% of the maximum possible effect.Potency - concentration of an agonist required to produce 50% of the maximum possible effect Testing with Receptors